Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC–MS/MS

Vu, Dinh Hoa; Koster, Remco A.; Bolhuis, Mathieu S.; Greijdanus, Ben; Altena, Richard van; Nguyen, Dinh-Duc; Brouwers, Jacobus; Uges, Donald; Alffenaar, Jan-Willem

doi:10.1016/j.talanta.2013.12.043

Cited by 72 publications

(70 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[24] Vu and co-workers thereafter examined the simultaneous determination of rifampicin, clarithromycin, and their metabolites on basis of DBS. [29] Both studies showed promising results for the use of DBS in TDM of anti-TB drugs. A recent review described which drugs used for pulmonary infections were potential candidates for the development and application of DBS monitoring from an analytical and clinical point of view.…”

Section: Dried Blood Spotsmentioning

confidence: 95%

“…They also showed that rifampicin was stable for 2 months at ambient temperature. [29] Because DBS improves stability, due to the use of dried blood, it could provide an answer for patients in remote areas where the temperature and humidity are high. Stability of samples under high temperature and humidity is of the utmost importance, because most of the new TB cases in 2014 were diagnosed in Southeast Asia and western Pacific regions (58%) and the African region (29%).…”

Section: Dried Blood Spotsmentioning

confidence: 99%

“…[29] However, some issues need to be addressed before DBS can be implemented for TDM. DBS has only been validated for a few drugs, which have been marked with yes in Table 1.…”

Section: Dbsmentioning

confidence: 99%

See 2 more Smart Citations

Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis

Zuur

Bolhuis

Anthony

et al. 2016

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

Introduction: Tuberculosis remains a global health problem and pharmacokinetic variability has been postulated as one of the causes of treatment failure and acquired drug resistance. New developments enable implementation of therapeutic drug monitoring, a strategy to evaluate drug exposure in order to tailor the dose to the individual patient, in tuberculosis treatment. Areas covered: Literature on pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs was explored to evaluate the effect of drug exposure in relation to drug susceptibility, toxicity and efficacy. New, down-sized strategies, like dried blood spot analysis and limited sampling strategies are reviewed. In addition, molecular resistance testing of Mycobacteria tuberculosis, combining a short turn-around time with relevant information on drug susceptibility of the causative pathogen was explored. Newly emerging host biomarkers provide information on the response to treatment. Expert opinion: Therapeutic drug monitoring can minimize toxicity and increase efficacy of tuberculosis treatment and prevent the development of resistance. Dried blood spot analysis and limited sampling strategies, can be combined to provide us with a more patient friendly approach. Furthermore, rapid information on drug susceptibility by molecular testing, and information from host biomarkers on the bacteriological response, can be used to further optimize tuberculosis treatment. ARTICLE HISTORY

show abstract

Section: Dried Blood Spotsmentioning

confidence: 95%

Section: Dried Blood Spotsmentioning

confidence: 99%

See 1 more Smart Citation

Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis

Zuur

Bolhuis

Anthony

et al. 2016

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

show abstract

“…The extraction method for plasma and DBSs was adapted from a previously reported method (19), in which chelation agents were added to prevent RIF binding to ferrous and ferric ions. Plasma was extracted by using a protein precipitation method.…”

Section: Methodsmentioning

confidence: 99%

Validation and Application of a Dried Blood Spot Assay for Biofilm-Active Antibiotics Commonly Used for Treatment of Prosthetic Implant Infections

Knippenberg

Page‐Sharp

Salman

et al. 2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

d Dried blood spot (DBS) antibiotic assays can facilitate pharmacokinetic (PK)/pharmacodynamic (PD) studies in situations where venous blood sampling is logistically difficult. We sought to develop, validate, and apply a DBS assay for rifampin (RIF), fusidic acid (FUS), and ciprofloxacin (CIP). These antibiotics are considered active against organisms in biofilms and are therefore commonly used for the treatment of infections associated with prosthetic implants. A liquid chromatography-mass spectroscopy DBS assay was developed and validated, including red cell partitioning and thermal stability for each drug and the rifampin metabolite desacetyl rifampin (Des-RIF). Plasma and DBS concentrations in 10 healthy adults were compared, and the concentration-time profiles were incorporated into population PK models. The limits of quantification for RIF, Des-RIF, CIP, and FUS in DBS were 15 g/liter, 14 g/liter, 25 g/liter, and 153 g/liter, respectively. Adjusting for hematocrit, red cell partitioning, and relative recovery, DBS-predicted plasma concentrations were comparable to measured plasma concentrations for each antibiotic (r > 0.95; P < 0.0001), and Bland-Altman plots showed no significant bias. The final population PK estimates of clearance, volume of distribution, and time above threshold MICs for measured and DBS-predicted plasma concentrations were comparable. These drugs were stable in DBSs for at least 10 days at room temperature and 1 month at 4°C. The present DBS antibiotic assays are robust and can be used as surrogates for plasma concentrations to provide valid PK and PK/PD data in a variety of clinical situations, including therapeutic drug monitoring or studies of implant infections. P harmacokinetic (PK)/pharmacodynamic (PD) studies of infectious diseases explore the triangular relationship between antibiotic exposure, the antibiotic susceptibility of the infecting organism (taken as the MIC), and predefined clinical outcomes (1). This allows estimation of microbiological susceptibility "breakpoints," facilitates the design of optimal dosing regimens (2), and provides data relating to the emergence of drug-resistant organisms (3, 4). Most PK/PD studies are performed in animal models or in highly selected samples of adults, such as patients in intensive care units, for whom sequential sampling of sufficient volumes of venous blood is both feasible and ethical. In contrast, PK/PD studies are rarely performed on other hospitalized or ambulatory patient populations due to difficulties associated with blood sampling. Relevant examples include patients receiving treatment for implant infections, young children, and patients treated in nonurban or resource-poor settings.Measurement of drug concentrations in dried blood spots (DBSs) represents a new approach to overcome the limitations of traditional therapeutic drug monitoring and PK/PD studies. DBSs are a convenient and inexpensive means of sampling and storage of whole blood for subsequent assays. Low-volume finger prick samples (10 to 20 l) are taken on f...

show abstract

“…interactions [36,[70][71][72][73]. Voriconazole has a nonlinear pharmacokinetic profile and there is a wide 418 intra and interindividual variety [71].…”

Section: Antifungal Drugs 415mentioning

confidence: 99%

Role of Therapeutic Drug Monitoring in Pulmonary Infections: Use and Potential for Expanded Use of Dried Blood Spot Samples

et al. 2015

View full text Add to dashboard Cite

Respiratory tract infections are among the most common infections in men. We reviewed literature to document their pharmacological treatments, and the extent to which therapeutic drug monitoring (TDM) is needed during treatment. We subsequently examined potential use of dried blood spots as sample procedure for TDM. TDM was found to be an important component of clinical care for many (but not all) pulmonary infections. For gentamicin, linezolid, voriconazole and posaconazole dried blood spot methods and their use in TDM were already evident in literature. For glycopeptides, beta-lactam antibiotics and fluoroquinolones it was determined that development of a dried blood spot (DBS) method could be useful. This review identifies specific antibiotics for which development of DBS methods could support the optimization of treatment of pulmonary infections

show abstract

Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC–MS/MS

Cited by 72 publications

References 27 publications

Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis

Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis

Validation and Application of a Dried Blood Spot Assay for Biofilm-Active Antibiotics Commonly Used for Treatment of Prosthetic Implant Infections

Role of Therapeutic Drug Monitoring in Pulmonary Infections: Use and Potential for Expanded Use of Dried Blood Spot Samples

Contact Info

Product

Resources

About